Deborah Doroshow, MD, PhD is a medical oncologist and clinical investigator at the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai who specializes in thoracic oncology and histology-agnostic early phase drug development. This application to the Early Career Cancer Clinical Investigator Award (ECIA) P30 Administrative Supplement (ECIA) describes Dr. Doroshow’s intent to expand her clinical trial research and leadership activities in 1) the Early Therapeutics Clinical Trials Network (ETCTN), 2) the Southwest Oncology Group (SWOG), and 3) the Division of Hematology and Oncology at Mount Sinai. In the ETCTN, she will become principal investigator of the existing Mount Sinai Early Drug Development Opportunity (EDDOP) grant. In that role, she will collaborate with junior faculty and hematology/oncology fellows to open existing ETCTN early phase clinical trials and will provide guidance and support regarding the submission of novel study concepts. As an individual investigator, she will submit at least one original early phase study concept to CTEP for consideration. As a member of the SWOG lung committee, Dr. Doroshow will co-chair a LUNG MAP substudy of trastuzumab deruxtecan in patients with advanced ERBB2 amplified NSCLC. She will join the locally advanced lung cancer committee and participate in ongoing efforts to analyze genomic characteristics of patient participants in previous and ongoing SWOG thoracic oncology trials. In the Tisch Cancer Institute and Division of Hematology and Medical Oncology, Dr. Doroshow will serve on the Data Safety Monitoring Committee and continue to lead the Investigator Initiated Trial (IIT) incubator workshops and serve on the IIT review committee. Her research and institutional work on improving the diversity of clinical trial participants will influence efforts in these three domains.